Dr. Virella Biosketch
Upcoming SlideShare
Loading in...5
×
 

Dr. Virella Biosketch

on

  • 400 views

 

Statistics

Views

Total Views
400
Views on SlideShare
400
Embed Views
0

Actions

Likes
0
Downloads
0
Comments
0

0 Embeds 0

No embeds

Accessibility

Categories

Upload Details

Uploaded via as Microsoft Word

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

Dr. Virella Biosketch Dr. Virella Biosketch Document Transcript

  • BIOGRAPHICAL SKETCH Provide the following information for the key personnel and other significant contributors in the order listed on Form Page 2. Follow this format for each person. DO NOT EXCEED FOUR PAGES. NAME POSITION TITLE Gabriel Virella Professor eRA COMMONS USER NAME virellag EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.) DEGREE INSTITUTION AND LOCATION YEAR(s) FIELD OF STUDY (if applicable) School of Medicine, University of Lisbon, M.D. 1967 Medicine Portugal University of Birmingham Medical School, U.K. Postdoc 1968-1969 Immunology National Institute of Medical Research, Mill Hill, Postdoc 1969-1970 Immunology U.K. Gulbenkian Institute of Science, Oeiras, Portugal Postdoc 1970-1971 Immunology School of Medicine, University of Lisbon, Ph.D. 1974 Microbiology Portugal Please refer to the application instructions in order to complete sections A, B, and C of the Biographical Sketch. Professional Experience: 1971 Research Assistant, Gulbenkian Institute of Science, Oeiras, Portugal; Head, Immunochemistry and Immunopharmacology Section, Pharmacology Laboratory 1972 - 1974 Graduate Research Assistant, Gulbenkian Institute of Science, Immunochemistry and Immunopharma-cology Section, Pharmacology Laboratory 1974 - 1975 Researcher, Gulbenkian Institute of Science, Immunochemistry and Immunopharmacology Section, Pharmacology Laboratory 1975 - 1976 Associate of the Department of Basic and Clinical Immunology and Microbiology, MUSC 1976 - 1978 Assistant Professor, Department of Basic and Clinical Immunology and Microbiology, MUSC 1978 - 1980 Associate Professor, Department of Basic and Clinical Immunology and Microbiology, MUSC 1980 - Present Professor, Department of Microbiology and Immunology, MUSC Honors and Awards: 1967 Award to the best graduation thesis presented to the Medical School of the University of Lisbon in 1966-67 (Studies on the alterations of serum proteins in malignant blood diseases) 1971 2nd Pfizer Award for Medical Research (Society of the Medical Sciences, Lisbon) 1973 lst Pfizer Award for Young Medical Researchers (Society of the Medical Sciences, Lisbon) 1981-Present Golden Apple Award, Best Teacher in Basic Sciences, Medical University of South Carolina (1981, 1987, 1991, 1995, 1997, 1999, 2001. 2003, 2005), ΑΩΑ, elected in 1988; Councilor (1993-2006); Teaching Excellence Award, Medical University of South Carolina (1996, 2006); Governor's Distinguished Professor Award (1996, 2006). 2002 Elected Honorary Alumnus, Medical University of South Carolina 2003 Robert J. Glaser ΑΩΑ/ AAMC Distinguished Teacher Award 2004 S.C. Governor’s Award for Excellence in Scientific Awareness 2005 Governor’s Award for Excellence in Scientific Awareness 2006 Cited as a Master Teacher by the Board of Trustees, Medical University of South Carolina Editorial Boards: Clinical Immunology 1979-present; Section Editor 1989-present; Clinical Immunology Newsletter 1979-1988; Journal of Clinical Microbiology 1981-1983; Clinical and Diagnostic Laboratory Immunology, member of the Editorial Board, 1993-present
  • B) Publications TEXTBOOKS: G. Virella (Ed.). NMS Microbiology and Infectious Diseases, 3rd Ed., Williams & Wilkins, 1997. (Polish Edition 2000, Urban & Partner, Wroclaw) G. Virella (Ed.). Introduction to Medical Immunology, Marcel Dekker, N.Y., 4th Ed., 1998. (Italian Edition, 1999, Piccin Nuova Libraria, Padua). G. Virella. NMS Q&A Microbiology, Immunology, and Infectious Diseases, Lippincott Williams & Wilkins, Philadelphia, 1999 G. Virella (Ed.) Medical Immunology, 6th Ed. Informa Healthcare USA, NY,10016, 2007 PUBLICATIONS: (Selected from a total of 212 articles) G. Virella, J.M. Kilpatrick, F. Chenais and H.H. Fudenberg. Isolation of soluble immune complexes from human serum: Combined use of polyethylene glycol precipitation, gel filtration, and affinity chromatography on protein A - sepharose. Methods in Enzymology, 74: 644-663, 1981. Chou YK, Sherwood T and Virella G. Erythrocyte-bound immune complexes trigger the release of interleukin-l from human monocytes. Cell Immun 91: 308, 1985. Sherwood TA and Virella G. The binding of immune complexes to human red cells: Complement requirements and fate of the RBC-bound IC after interaction with human phagocytic cells. Clin Exper Immun 64: 195, 1986. J.M. Kilpatrick, B. Hyman and G. Virella. Human endothelial cell damage induced by interactions between polymorphonuclear leukocytes and immune-complex-coated erythrocytes. Clinical Immunology and Immunopathology, 44: 335-347, 1987. J.M. Kilpatrick, A. Pitt, S. Allen, S.K. Ainsworth, J. Castriotta and G. Virella. Treatment of acute serum sickness by plasma ultrafiltration. American Journal of Medical Sciences, 293: 75-84, 1987. Griffith RL, Virella G, Stevenson HC and Lopes-Virella MF. Low density lipoprotein (LDL) metabolism by human macrophages activated with low density lipoprotein immune complexes: A possible mechanism of foam cell formation. J Exper Med 168: 1041-59, 1988. Gisinger C, Virella G and Lopes-Virella MF. Erythrocyte-bound low-density lipoprotein immune complexes lead to cholesteryl ester accumulation in human monocyte-derived macrophages. Clin Immun Immunopath 59: 37-52, 1991. Virella G, Virella I, Leman RB, Pryor MB, and Lopes-Virella MF. Anti-oxidized low-density lipoprotein antibodies in patients with coronary heart disease and normal healthy volunteers. Int J Clin Lab Res 23: 95-101, 1993. Virella G, Muñoz JF, Galbraith GM, Gissinger C, Chassereau C and Lopes-Virella MF. Activation of human monocyte-derived macrophages by immune complexes containing low density lipoprotein. Clin Immunol Immunopath 75: 179-89, 1995. Gergen PJ, McQuillan GM, Kiely M, Ezzati-Rice TM, Sutter RW and Virella G. Serologic immunity to tetanus in the U.S. population: Implications for national vaccine programs. New Eng J Med 332: 761-66, 1995. Mironova M, Lopes-Virella MF, and Virella G. Isolation and characterization of human anti-oxidized LDL auto- antibodies. Arterioscler Thrombos Vasc Biol 16: 222-29, 1996. Mironova M, Virella G, Virella-Lowell I and Lopes-Virella MF. Anti-modified LDL antibodies and LDL- containing immune complexes in well-controlled IDDM patients and healthy controls. Clin Immunol Immunopath 85: 73-82, 1997. Lopes-Virella MF, Binzafar N, Rackley S, Takei A, La Via M and Virella G. The uptake of LDL-IC by human macrophages: Predominant involvement of the Fc RI receptor. Atheroscler 135: 161-70, 1997. Koskinen S, Enockson C, Lopes-Virella MF and Virella G. Preparation of a human standard for the determination of the levels of antibodies to oxidatively modified low-density lipoproteins. Clin Diag Lab Immun 5: 817-22, 1998. Lopes-Virella MF, Virella G, Orchard TJ, Koskinen S, Evans RW, Becker DJ and Forrest KY. Oxidized LDL- antibodies and LDL-containing immune complexes as risk factors for coronary artery disease in diabetes mellitus. Clin Immun 90: 165-72, 1999. Orchard TJ, Virella G, Forrest KY, Becker DJ, and Lopes-Virella MF. Antibodies to oxidized LDL predict CAD in type 1 diabetes: A nested case control study from the Pittsburgh Epidemiology of Diabetes Complication study. Diabetes 48: 1454-58, 1999. Huang Y, Fleming AJ, Wu S, Virella G, Lopes-Virella MF. Fc-gamma receptor cross-linking by immune complexes induces matrix metalloproteinase-1 in U937 cells via mitogen-activated protein kinase. Arterioscler Thromb Vasc Biol. 12:2533-2538, 2000
  • Lopes-Virella MF, Koskinen S, Mironova M, Horne D, Klein R, Chasssereau C, Enockson C and Virella G. The preparation of copper-oxidized LDL for the measurement of oxidized LDL antibodies by EIA. Atheroscler 152: 107-15, 2000. Virella G, Koskinen S, Krings G, Onorato JM, Thorpe SR and Lopes-Virella M. Immunochemical characterization of purified human oxidized low-density lipoprotein antibodies. Clin Immun 95: 135-44, 2000. Mironova M, Klein RL, Virella G and Lopes-Virella MF. Anti-modified LDL antibodies, LDL-containing immune complexes, and susceptibility of LDL to in vitro oxidation in patients with type 2 diabetes. Diabetes 49: 1033-41, 2000. Vielma, S. Virella, G., Gorod, A.J., and Lopes-Virella, M.F. Chlamydophila pneumoniae infection of human aortic endothelial cells induces the expression of Fcγ Receptor II (FcγRII). Clinical Immunology, 104: 265-273, 2002 Virella, G., Atchley, D. Koskinen, S., Zheng, D., Lopes-Virella, M. F. Pro-atherogenic and pro-inflammatory properties of immune complexes prepared with purified human oxLDL antibodies and human oxLDL. Clinical Immunology, 105: 81-92, 2002. Atchley, D., Lopes-Virella, M. F., Zheng, D., Virella, G., and the DCCT/EDIC Research Group. Oxidized LDL - Anti-Oxidized LDL Immune Complexes and Diabetic Nephropathy. Diabetologia, 45: 1562-1571, 2002 Virella, G. and Lopes-Virella, M.F. Humoral Immunity and Atherosclerosis. Nature Medicine, 9: 243-244, 2003 Virella, G., Thorpe, S, Alderson,N.L., Stephan, E.M., Atchley, D., Wagner, F., Lopes-Virella, M. F. and the DCCT/EDIC Research Group. Autoimmune response to advanced glycosylation end-products of human low density lipoprotein. J. Lipid Research 443:487-493, 2003 Lopes-Virella, M.F. and Virella, G. The role of immune and inflammatory processes in the development of macrovascular disease in diabetes. Frontiers in Bioscience, 8: s750-768, 2003 Virella, G. and Lopes-Virella, M. F. Lipoprotein autoantibodies: measurement and significance. Clinical and Diagnostic Laboratory Immunology, 10:499-505, 2003 Lopes-Virella, M.F., Mironova, M., Stephan, E., Durazo-Arvizu, R. and Virella, G. Role of simvastatin as an immunomodulator in type 2 diabetes. Diabetes Care, 27: 908-913, 2004. Virella, G., Thorpe, S, Alderson,N.L., Derrick, M. B., Chassereau, C.; Rhett, J.M. and Lopes-Virella, M.F. Definition of the immunogenic forms of modified human LDL recognized by human autoantibodies and by rabbit hyperimmune antibodies. J. Lipid Research, 45:1859-67, 2004. Virella, G., Derrick, M. B., Pate, V., Chassereau, C., Thorpe,, S.R. and Lopes-Virella, M.F. Development of capture assays for different modifications of human Low-Density Lipoprotein. Clin. Diagn. Lab. Immunol., 12: 68-75, 2005. Costacou, T., Lopes-Virella, M.F., Zgibor, J. C., Virella, G., Otvos, J., Walsh, M., Orchard, T.J. Markers of endothelial dysfunction in the prediction of coronary artery disease in type 1 diabetes. The Pittsburgh Epidemiology of Diabetes Complications Study. J. Diabetes and its Complications, 19:183-193, 2005 Lopes-Virella, M.F., Thorpe, S, Derrick, M. B., Chassereau, C., and Virella, G. The Immunogenicity of Modified Lipoproteins. Ann. N.Y. Acad. Sci., 1043:367-378, 2005. Yishak, A.A., Costacou, T., Virella, G., Zgibor, J., Fried, L., Walsh, M., Evans, R.W., Lopes-Virella, M., Kagan, V.E., Otvos, J., and Orchard, T.J. Novel predictors of overt nephropathy in subjects with type 1 diabetes. A nested case control study from the Pittsburgh Epidemiology of Diabetes Complications (EDC) cohort. Nephrology, Dialysis, and Transplantation, 21: 93-100, 2006. Lopes-Virella, M. F., B. McHenry M, L. S., Y. E., P. F. Wilson, D. T. Lackland, T. Lyons, J. A. J., G. Virella, and D. E. R. Group.. Immune complexes containing modified lipoproteins are related to the progression of internal carotid intima-media thickness in patients with type 1 diabetes. Atherosclerosis 190: 359-69, 2007. (Epub 2006 Mar 10) Saad, A.F., Virella, G., Chassereau, C., Boackle, R.J. and Lopes-Virella, M.F. Autoimmune OxLDL Immune- Complexes Activate The Classical Pathway Of Complement And Induce Cytokine Production By Mono Mac 6 Cells and Primary Human Macrophages. J. Lipid Research, 47:1975-83, 2006 [Epub ahead of print]
  • C) Research Support: (Ongoing or completed last three years) CURRENT RESEARCH SUPPORT 1. VA Merit Review Research Program-Year 20: Lopes-Virella (PI), 4/1/85-3/31/07 Lipoprotein Metabolism and Cell-Lipoprotein Interactions in Diabetes Mellitus The major goal of this project is to isolate and characterize immune complexes containing modified lipoproteins in patients with type 2 diabetes and develop assays to characterize them in a large cohort of patients. Role: Co-investigator 2. 1-2006-49 JDRFI, Lopes-Virella (PI), 3/1/06-2/28/09 Immune Mechanisms of Micro/Macrovascular Disease in Type 1 Diabetes. The major goal of this project is to isolate and characterize immune complexes containing modified lipoproteins in patients with type 1 diabetes and develop assays to characterize them. Role: Co-investigator COMPLETED RESEARCH SUPPORT (LAST 3 YEARS): 1. PO1-HL-55782-09 Lopes-Virella (PI) NIH/NHLBI, 9/1/96-8/31/06 Markers and Mechanisms of Macrovascular Disease in Diabetes Mellitus The study will assess risk factors and mechanisms for micro and macrovascular complication in two large cohorts: DCCT/EDIC (type 1 DM) and VA Diabetes trial (Type 2 DM) Role: Co-investigator 1. R01-HL46815 Lopes-Virella (PI) :NHLBI, NIH, 12/1-94-11/30/2003 Macrophage Activation and Lipoprotein Metabolism This major goal of this project was to study the regulation of LDL receptor in human macrophages stimulated by LDL containing immune complexes Role: Co-investigator 2. R01 DK34818 Orchard (PI) NIH/NIDDK 3/1/1999-2/28/01 Epidemiology of Diabetic complications: Phase II This project main goal was to measure the levels of adhesion molecules and immune complexes in a case-control cohort from the Epidemiology of diabetes complications Study Role: Co-Investigator (Subcontract to MUSC). 3. 1-2002-812-03 Lopes-Virella (PI) JDRFI 7/1/02-6/30/05 Immune Mechanisms of Micro/Macrovascular Disease in Type 1 Diabetes The major goal of this project is to isolate and characterize immune complexes containing modified lipoproteins in patients with type 1 diabetes and develop assays to characterize them in the DCCT/EDIC cohort Role: Co-investigator.